Globeflex Capital L P Takes Position in Insulet Co. (NASDAQ:PODD)

Globeflex Capital L P purchased a new stake in Insulet Co. (NASDAQ:PODD) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 500 shares of the medical instruments supplier’s stock, valued at approximately $131,000.

A number of other institutional investors have also modified their holdings of the company. Integrated Wealth Concepts LLC boosted its holdings in shares of Insulet by 1.7% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock valued at $596,000 after buying an additional 42 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Insulet by 1.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock valued at $1,146,000 after buying an additional 43 shares in the last quarter. Glenmede Trust Co. NA boosted its stake in Insulet by 2.3% in the 3rd quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock worth $484,000 after purchasing an additional 47 shares in the last quarter. Graypoint LLC boosted its stake in Insulet by 5.3% in the 4th quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock worth $243,000 after purchasing an additional 47 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB boosted its stake in Insulet by 9.6% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier’s stock worth $140,000 after purchasing an additional 47 shares in the last quarter.

Insider Buying and Selling

In related news, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.47% of the stock is owned by insiders.

Insulet Price Performance

NASDAQ:PODD opened at $255.44 on Friday. The firm has a market cap of $17.94 billion, a price-to-earnings ratio of 44.12, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29. The company has a 50 day moving average price of $272.54 and a 200-day moving average price of $254.96. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping the consensus estimate of $1.00 by $0.15. The company had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Equities research analysts forecast that Insulet Co. will post 3.92 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on PODD. TD Cowen lifted their target price on shares of Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Piper Sandler lifted their target price on shares of Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Citigroup lifted their target price on shares of Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Canaccord Genuity Group lifted their target price on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Finally, Royal Bank of Canada initiated coverage on shares of Insulet in a research report on Thursday, March 6th. They set an “outperform” rating and a $340.00 price target for the company. Four investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and an average target price of $292.06.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.